Medscape5d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Neurology Advisor5d
Study Finds Exenatide Not Beneficial for Parkinson Disease
No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying treatment for Parkinson disease. HealthDay News — The glucagon-like peptide-1 receptor agonist exenatide does ...
Medscape5d
Sitagliptin: An Oral Agent for Glucose Control
Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...